Corteva vs Scotts Miracle-Gro
Add, change or remove companies; up to four.
The short version
- Corteva is the larger business, with $17.4B of revenue in fiscal 2025 against $3.4B for Scotts Miracle-Gro, about 5.1 times as much.
- Corteva grew revenue faster (2.9%, against −3.9%).
- Corteva turned more of its sales into free cash flow (16.2% FCF margin, against 8.0%).
- Scotts Miracle-Gro earned a higher return on the capital invested in it (13.4%, against 5.8%).
- Investors pay more for each dollar of Scotts Miracle-Gro’s earnings: a P/E of 50.2x against 8.2x for Corteva.
| Latest fiscal year | CTVA · FY25 | SMG · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | $3.5B |
| Revenue | $17.4B | $3.4B |
| Free cash flow | $2.8B | $274M |
| Net income | $1.1B | $145M |
| Growth | ||
| Revenue growth | 2.9% | −3.9% |
| 5-year growth | 4.1% | −3.8% |
| Share count change | −2.1% | 3.4% |
| Profitability | ||
| Gross margin | 47.3% | 30.6% |
| Operating margin | — | 10.5% |
| Net margin | 6.3% | 4.3% |
| FCF margin | 16.2% | 8.0% |
| Return on capital | 5.8% | 13.4% |
| Return on equity | 4.6% | — |
| Balance sheet | ||
| Net debt | −$2.0B | $2.1B |
| Net debt / EBITDA | −0.6x | 4.8x |
| Dividends and buybacks | $1.5B | $173M |
| Valuation & quality | ||
| P/E | 8.2x | 50.2x |
| Piotroski F-score | 8 | 6 |
Revenue
FY16
CTVA —
SMG $2.5B
FY17
CTVA —
SMG $2.6B
FY18
CTVA $14.3B
SMG $2.7B
FY19
CTVA $13.8B
SMG $3.2B
FY20
CTVA $14.2B
SMG $4.1B
FY21
CTVA $15.7B
SMG $4.9B
FY22
CTVA $17.5B
SMG $3.9B
FY23
CTVA $17.2B
SMG $3.6B
FY24
CTVA $16.9B
SMG $3.6B
FY25
CTVA $17.4B
SMG $3.4B
CTVA
SMG
Operating margin
FY16
CTVA —
SMG 17.9%
FY17
CTVA —
SMG 16.4%
FY18
CTVA —
SMG 7.5%
FY19
CTVA —
SMG 13.0%
FY20
CTVA —
SMG 14.2%
FY21
CTVA —
SMG 14.7%
FY22
CTVA —
SMG −11.1%
FY23
CTVA —
SMG −4.9%
FY24
CTVA —
SMG 5.9%
FY25
CTVA —
SMG 10.5%
CTVA
SMG
Free cash flow
FY16
CTVA —
SMG $186M
FY17
CTVA —
SMG $294M
FY18
CTVA −$1.0B
SMG $274M
FY19
CTVA −$93.0M
SMG $184M
FY20
CTVA $1.6B
SMG $495M
FY21
CTVA $2.2B
SMG $165M
FY22
CTVA $267M
SMG −$243M
FY23
CTVA $1.2B
SMG $438M
FY24
CTVA $1.5B
SMG $584M
FY25
CTVA $2.8B
SMG $274M
CTVA
SMG
Return on capital
FY16
CTVA —
SMG 15.7%
FY17
CTVA —
SMG 14.1%
FY18
CTVA —
SMG 9.3%
FY19
CTVA −0.3%
SMG 13.1%
FY20
CTVA 3.2%
SMG 19.5%
FY21
CTVA 8.3%
SMG 20.8%
FY22
CTVA 5.6%
SMG −11.2%
FY23
CTVA 4.7%
SMG −5.1%
FY24
CTVA 4.2%
SMG 8.0%
FY25
CTVA 5.8%
SMG 13.4%
CTVA
SMG
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.